A Randomised controlled pharmaco-clinical study to evaluate the efficacy of Mundi In Medodushti (Dyslipidemia).

A Randomised controlled pharmaco-clinical open labelled study to evaluate the efficacy of Mundi (Sphaeranthus indicus.L.) In Medodushti (Dyslipidemia). - nil

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/05/087204

Enrollment

Registered

2025-05-20

Start date

Unknown

Completion date

Unknown

Last updated

2025-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E785- Hyperlipidemia, unspecified

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Patients Recently Diagnosed With Dyslipidemia Age Between 18-60yrs Known Case Of Dyslipidemia Patients Not On Standard Therapy Since 1 Month For Test Group A Patient Willing To Consent In Trial

Exclusion criteria

Exclusion criteria: Patient Diagnosed With Chronic Disorders Patient On Drugs That Induced Hyperlipidemia Undergoing Psychotic Therapy Pregnant And Lactating Women Chronic Alcoholic And Smokers Past Drug Allergies MALABSORPTION DISORDERS

Design outcomes

Primary

Measure	Time frame
IMPROVEMENT IN LIPID PROFILETimepoint: Assessment lipid profile at baseline and 12 weeks followup at 4 weeks, 8 weeks and 12 weeks	—

Secondary

Measure	Time frame
IMPROVEMENT IN VO2MAX EVALUATION OF TOLERABILITY BMITimepoint: assessment at baseline 4 weeks 8 weeks & 12 weeks	—

Countries

India

Contacts

Public ContactDr Shraddha Nayak

D Y Patil School Of Ayurveda Nerul Navi Mumbai

shraddha.nayak@dypatil.edu9619016727

Outcome results